A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-03

Study Completion Date

2020-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants with Non-Small Cell Lung Cancer (NSCLC), Performance Status (PS) 0-2, not suitable for concurrent Chemo-Radiotherapy (CTRT), will be treated with standard radiotherapy (radical or palliative). Archival tumour biopsies will be analysed for baseline Programmed Death Ligand 1 (PD-L1) expression. Some participants will have a biopsy before radiotherapy if the archive biopsy is not suitable. Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week of radiotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy

NCT02869685

NSCLC

COMPLETED NA

Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer

NCT06086574

Lung Cancer Stage III

UNKNOWN

Prognostic Value of PD-L1 in NSCLC

NCT03078959

Carcinoma, Non-Small-Cell Lung

UNKNOWN

PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer

NCT02827344

Lung Cancer

COMPLETED

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

NCT06869239

Limited-stage Small Cell Lung Cancer (LS-SCLC)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this prospective, multicentre, non-randomised translational study is to provide proof of feasibility of achieving paired biopsies for PD-L1 assessment in patients with NSCLC treated with palliative or radical radiotherapy. This is a non-CTIMP study.

All participants will have a minimum of 1 mandatory biopsy (during radiotherapy \[irradiated site\]) and the potential to have a pre-treatment biopsy if archival biopsy does not meet the suitability criteria.

Participants will have up to a maximum of 2 additional optional biopsies (during radiotherapy \[within the RT field e.g supraclavicular fossa node\], \[outside RT field e.g. skin met\]).

Blood samples will also be taken on study at specified time points for immune monitoring (exploratory endpoints).

The study will be carried out in two stages as follows:

Stage 1:

Following the enrolment of the first 15 evaluable participants, an interim analysis will take place by the Trial Steering Committee (TSC). The TSC will make a recommendation on whether recruitment should continue to the Trial Management Group (TMG).

Stage 2:

A further 15 evaluable participants will be recruited onto the study to achieve a total of 30 evaluable participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Small Cell Lung Cancer

Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.

Biopsy and blood samples

Intervention Type PROCEDURE

Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.

Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.

Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy and blood samples

Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.

Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.

Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed NSCLC
* Diagnostic/pre-treatment biopsy suitable for PD-L1 analysis\*
* Tumour judged inoperable by a lung MDT
* Tumour that is accessible to core biopsy
* Age 18 and over, no upper age limit
* Performance status (PS) - ECOG 0-2
* Participant considered suitable for radiotherapy (palliative or radical) or sequential chemo-radiotherapy
* Before participant registration, written informed consent must be given according to GCP and national regulations

* Pre-treatment biopsy must be from gross tumour volume within planned radiation field, and must also:

* have been formalin fixed for \>12h and ≤24h
* have tumour tissue and morphology confirmed by H\&E staining
* contain sufficient tumour cells (\>100) to determine PD-L1 status

Exclusion Criteria

* Participant suitable for standard concurrent CTRT
* Participant deemed unsuitable for repeat biopsies in the opinion of the treating oncologist
* Participant known to have an EGFR mutation or an ALK rearrangement
* Intercurrent or history of hepatitis B, C or human immunodeficiency virus infection, if known
* Participants who have received more than 1 line of chemotherapy prior to radiotherapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No